Combining Incretin-Based Therapies With Insulin
Author:
Affiliation:
1. Department of Diabetes and Endocrinology, Royal Liverpool University Hospital, Liverpool, U.K.
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
https://diabetesjournals.org/care/article-pdf/36/Supplement_2/S226/483974/s226.pdf
Reference42 articles.
1. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function;Mudaliar;Am J Med,2010
2. The biology of incretin hormones;Drucker;Cell Metab,2006
3. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues;Tews;Horm Metab Res,2008
4. Time for testing incretin therapies in early type 1 diabetes?;Bosi;J Clin Endocrinol Metab,2010
5. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting;Yoon;Clin Ther,2009
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL);Advances in Therapy;2022-10-07
2. Kontrol altında olmayan tip 2 diyabetes mellitus hastalarında insülin tedavisinden eksenatid bazlı tedaviye geçişin etkinliği;Cukurova Medical Journal;2020-09-30
3. Efficacy and safety of gemigliptin as add‐on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study);Diabetes, Obesity and Metabolism;2019-10-08
4. Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial;Advances in Therapy;2019-07-29
5. Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice;Diabetes Spectrum;2019-05-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3